Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Monday, September 07. 2015
  • Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC) program to develop new antibiotic treatments for cystic fibrosis and bronchiectasis
Friday, August 28. 2015
Basel, Switzerland, August 28, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Basilea named Dr. Günter Ditzinger, currently Head of Pharmaceutics, to succeed Dr. Heinze-Krauss in the role of Chief Technology Officer and as a member of the management committee effective February 1, 2016.
Friday, August 14. 2015
  • Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union
  • Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched in four European countries
  • Ceftobiprole designated as a Qualified Infectious Disease Product for the treatment of lung and skin infections by U.S. FDA
  • Additional oncology program (panRAF kinase inhibitor BAL3833) entered phase 1 of clinical development
  • Cash and short-term investments of CHF 218.4 million
Wednesday, August 12. 2015
Basel, Switzerland, August 12, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product. The designation relates to the potential use of the drug in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Infectious Diseases
Society of America